CompletedPhase 3NCT03181932
AeroVanc in the Treatment of Methicillin-resistant Staphylococcus Aureus Infection in Patients With Cystic Fibrosis
Studying Cystic fibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Savara Inc.
- Principal Investigator
- Patrick Flume, MDMedical University of South Carolina
- Intervention
- Vancomycin inhalation powder(drug)
- Enrollment
- 188 enrolled
- Eligibility
- 6 years · All sexes
- Timeline
- 2017 – 2021
Study locations (30)
- Pulmonary Associates of Mobile, Mobile, Alabama, United States
- Phoenix Children's Hospital, Phoenix, Arizona, United States
- University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- Miller Childrens Hospital MemorialCare Health System Pediatric Pulmonology, Long Beach, California, United States
- Children's Hospital Los Angeles, Los Angeles, California, United States
- University of Southern California Keck Medical Center of USC, Los Angeles, California, United States
- UC Davis Medical Center, Sacramento, California, United States
- Children's Hospital Colorado, Aurora, Colorado, United States
- National Jewish Health Adult Cystic Fibrosis Center, Denver, Colorado, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- University of Florida Pediatrics, Gainesville, Florida, United States
- Memorial Healthcare System, Hollywood, Florida, United States
- Nemours Childrens Specialty Care, Jacksonville, Florida, United States
- University of Miami Bachelor Children's Hospital, Miami, Florida, United States
- Central Florida Pulmonary Group, Orlando, Florida, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03181932 on ClinicalTrials.govOther trials for Cystic fibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT04530383Metformin for People With CFRD on CFTR Modulator Therapy to Improve Ion Channel FunctionUniversity of Kansas Medical Center
- RECRUITINGPHASE2NCT07450547Phase 2 Study to Assess the Safety and Efficacy of ANG003Anagram Therapeutics, Inc.
- RECRUITINGPHASE1NCT07437105Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy ParticipantsVertex Pharmaceuticals Incorporated
- RECRUITINGNANCT07436351ACT With CF Self-Help ToolkitThomas Jefferson University
- RECRUITINGNCT07369414Environmental Reservoirs of Non-tuberculous Mycobacteria in Cystic Fibrosis Households: A Case-control Study of Exposure Risk at HomeResearch Center Borstel
- RECRUITINGNANCT07314229Prevalence of Exercise-induced Ventilatory Limitation and Associated Factors in Patients With Cystic Fibrosis Receiving Elexacaftor-Tezacaftor-IvacaftorUniversity Hospital, Lille
- RECRUITINGNCT07083557Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)Bettina Mittendorfer
- RECRUITINGNCT07505797ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE)iSono Health, Inc.